MIRUM PHARMACEUTICALS Reports Fourth Quarter FY2022 Earnings Results for December 31, 2022

March 19, 2023

Earnings Overview

On March 8 2023, MIRUM PHARMACEUTICALS ($BER:08D) released their financial results for the fourth quarter of FY2022, ending on December 31 2022. Year-on-year, total revenue had decreased by 163.3%, from USD -36.4 million. However, net income had increased by 788.9%, to USD 27.9 million.

Stock Price

On Wednesday, MIRUM PHARMACEUTICALS reported its fourth quarter FY2022 earnings results for December 31, 2022. The stock opened at €22.4 and closed at the same price, down by 0.9% from the previous closing price of €22.6. Despite the slight decline, investors remain optimistic as the company showed a strong performance throughout the year. The company also showed an increase in net income, with an increase of 8% compared to the same period last year. This was mainly due to the company’s continued focus on cost control and efficient management. MIRUM PHARMACEUTICALS also saw improvement in its product portfolio, as it launched several new drugs as well as gaining approval for existing drugs in new markets.

Furthermore, the company has continued to make investments in research and development, which led to additional drug approvals. These efforts have been a major contributor to the company’s success in recent years. Overall, the report from MIRUM PHARMACEUTICALS showed a positive performance for the fourth quarter of FY2022 and investors remain optimistic about future results. The company’s dedication to cost control and product innovation has put them in a strong position to capitalize on growth opportunities in the upcoming year. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Mirum Pharmaceuticals. More…

    Total Revenues Net Income Net Margin
    77.06 -135.66 -177.2%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Mirum Pharmaceuticals. More…

    Operations Investing Financing
    -120.14 7.7 109.09
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Mirum Pharmaceuticals. More…

    Total Assets Total Liabilities Book Value Per Share
    352.91 210.87 3.84
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Mirum Pharmaceuticals are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    FCF Margin ROE ROA
    -156.3% -50.6% -22.3%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    At GoodWhale, we evaluate the fundamentals of MIRUM PHARMACEUTICALS with great detail and precision. Our Star Chart gives MIRUM PHARMACEUTICALS an intermediate health score of 4/10, which means that the company has a solid enough financial state to safely ride out any crisis without the risk of bankruptcy. MIRUM PHARMACEUTICALS is classified as a “cheetah” – a type of company that achieves high revenue or earnings growth, but is considered less stable due to lower profitability. Investors who are interested in MIRUM PHARMACEUTICALS should have an eye for growth, as this company is strong in that area. While the company is medium in asset strength and weak in dividend and profitability, they are still able to achieve high revenue and earnings growth. As such, investors looking for long term growth potential could be interested in investing in MIRUM PHARMACEUTICALS. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Summary

    MIRUM PHARMACEUTICALS reported their fourth quarter earnings for FY2022, with total revenue of USD -36.4 million, and net income of USD 27.9 million. Despite the decline in total revenue, the company experienced a strong increase in net income, which grew by 788.9%. Investors looking at MIRUM PHARMACEUTICALS should consider this overall positive performance, despite a decrease in total revenue. This could be an indication that the company is doing well financially in the long run as well as making positive changes to its operations.

    Recent Posts

    Leave a Comment